Vienna, 25 February 2010. With immediate effect AFFiRiS AG is starting a development program for vaccination against hypertension. For this project the Austrian Research Promotion Agency (FFG) is providing development funds of up to EUR 1.2 million.
With today's announcement four of the current seven vaccine projects of AFFiRiS AG are in the public domain. As with the other vaccines under development – to treat Alzheimer's disease, Parkinson's disease and atherosclerosis – the new vaccine will be based on the company's own AFFITOME® technology. However, for the first time it is now being used against a human hormone. The reason for this announcement is the gratifying approval of significant development funds by the Austrian Research Promotion Agency, FFG.